NEW APPROACHES TO BRAIN TUMOR THERAPY--A CNS CONSORTIUM

描述：(申请人描述) 这项建议的主要长期目标是改善 成人原发性脑肿瘤的治疗结果。这将是 通过Ph a se 1/11对有前景的新药物的临床评估完成， 生物途径和给药根在治疗中的作用 通过建立中枢神经系统的原发性恶性肿瘤 财团的成员。该财团是专门设计的，旨在将 聚焦十三大杰出医疗机构的丰富资源和能力 机构承担对原发性脑瘤的责任。为了达到这一目标， 财团将依靠其内部的特殊力量和能力 每个参与机构和财团内部作为一个整体。这个 宾夕法尼亚大学医学中心有大量的成年人 原发性脑肿瘤患者，2)专家多学科临床 护理这些患者的团队，3)广泛的临床和实验室 研究人员，4)数量惊人的正在进行的高质量临床 相关的、同行评审的、由NIH资助的临床和实验室脑肿瘤 研究项目，5)国家公认的肿瘤学专业知识， 药理学、新药开发、I/II期临床试验、 神经外科和神经病理学，6)广泛的统计，数据管理， 和多机构研究的协调，以及7)例外 在临床护理和研究方面享有卓越的声誉。该财团 通过定义良好且运行顺畅的 组织结构，注重临床试验设计、方案 开发、质量控制、研究监测和数据管理以及 分析。该议定书次要长期目标是利用这一点 财团将共享人脑肿瘤标本和其他临床标本 和实验室数据，以收集与1)有关的其他研究 原发脑肿瘤的基础生物学，2)新的神经药理学 原发脑肿瘤的治疗，以及3)改善护理和质量 成人原发性脑瘤患者的生活状况。这一目标将会实现 利用参与机构和NABTT的优势 相关生物学研究中心、NABTT药理学中心和 NABTT在科学委员会工作。

DESCRIPTION: (Applicant's Description) The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by P h a se 1/11 clinical evaluations of promising new agents, biological a p proaches, and roots of administration in the treatment of primary malignancies of the central nervous system through the establishment of the consortium. This consortium is specifically designed to combine and focus experienced resources and capabilities of thirteen Outstanding medical institutions to bear on primary brain tumors. To meet this objective, the consortium will rely on the special strength and abilities that rest within each participating institution and within the consortium as a whole. The University of Pennsylvania Medical Center has 1) a large number of adult patients with primary brain tumors, 2) expert Mult-disciplinary clinical teams to care for these patients, 3) extensive clinical and laboratory researchers, 4) a striking number of on-going high quality, clinically relevant, peer reviewed and NIH funded clinical and laboratory brain tumor research projects, 5) nationally recognized expertise in Oncology, Pharmacology, new drug development, Phase I/II clinical trials, Neurosurgery, and Neuropathology, 6) extensive statistics, data management, and coordination of multi-institutional studies, and 7) exceptional reputation for excellence in clinical care and research. The consortium adds these strengths with a well defined and smoothly functioning organizational structure, and emphasis on clinical trial design, protocol development, quality control, study monitoring and data management and analysis. The secondary long-term objective of this protocol is to use this consortium to share human brain tumor specimens as well as other clinical and laboratory data to collect additional research pertaining to 1) the basic biology of primary brain tumors, 2) the Neuropharmacology of new therapies for primary brain tumors, and 3) improving the care and quality of life of adults with primary brain tumors. This objective will be reached using the strengths of the participating institutions and the NABTT correlative biology research center, the NABTT pharmacology center, and the NABTT working in scientific committees.